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Population-based incidence of myeloid 
malignancies: fifteen years of epidemiological data
in the province of Girona, Spain
Myeloid malignancies (MMs) are a heterogeneous group
of hematologic malignancies presenting different inci-
dence, prognosis and survival.1-3 Changing classifications
(FAB 1994, WHO 2001 and WHO 2008) and few available
epidemiological data complicate incidence comparisons.4,5
Taking this into account, the aims of the present study
were: a) to calculate the incidence rates and trends of MMs
in the Province of Girona, northeastern Spain, between
1994 and 2008 according to the WHO 2001 classification;
and b) to predict the number of MMs cases in Spain during
2013. Data were extracted from the population-based
Girona Cancer Registry (GCR) located in the north-east of
Catalonia, Spain, and covering a population of 731,864
inhabitants (2008 census). Cases were registered according
to the rules of the European Network for Cancer Registries
and the Manual for Coding and Reporting Haematological
Malignancies (HAEMACARE project). To ensure the com-
plete coverage of MMs in the GCR, and especially myelo-
proliferative neoplasms (MPN) and myelodysplastic syn-
dromes (MDS), a retrospective search was performed. The
ICD-O-2 (1990) codes were converted into their corre-
sponding ICD-O-3 (2000) codes, including MDS, poly-
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Table 1. Number of cases, median age, incidence rates and sex ratio of myeloid malignancies diagnosed in Girona province (1994-2008)
according to the 2001 WHO classification. 
N.  of. Median age ASRE Sex
Entities cases % Men Women CR Men Women All Ratio
Acute myeloid leukemia 319 100 68 68 3.60 3.48 2.40 2.91 1.28*
AML with recurrent 35 11.0 52 54 0.40 0.45 0.34 0.39 1.32
cytogenetic abnormalities
AML with t(8;21)(q22;q22) 4 1.3 17 74 0.05 0.08 0.01 0.05 3.50
AML with 11q23 abnormalities 3 0.9 27 57 0.03 0.02 0.05 0.04 0.40
AML with inv(16)(p13;q22) 5 1.6 66 57 0.06 0.09 0.03 0.06 4.50
or t(16;16)(p13;q11)
AML with t(15;17)(q22;q11-12) 23 7.2 51 46 0.26 0.27 0.25 0.25 1.08
AML with multilineage dysplasia 46 14.4 71 78 0.52 0.46 0.28 0.36 1.31
AML and MDS therapy related 9 2.8 59 66 0.10 0.07 0.12 0.09 0.50
AML NOC 171 53.6 64 65 1.93 1.90 1.37 1.62 1.25
AML, minimal differentiated 19 6.0 66 62 0.22 0.19 0.22 0.20 0.87
AML, without maturation 37 11.6 62 68 0.42 0.37 0.32 0.34 0.95
AML, with maturation 31 9.7 61 61 0.35 0.44 0.21 0.32 2.09
Acute myelomonocytic leukemia 38 11.9 52 63 0.43 0.52 0.25 0.38 1.97
Acute monoblastic and monocytic leukemia 24 7.5 72 79 0.27 0.22 0.19 0.21 0.86
Acute erythroid leukemia 9 2.8 75 43 0.10 0.07 0.11 0.08 0.82
Acute megakaryoblastic leukemia 3 0.9 75 81 0.03 0.03 0.01 0.02 2.50
Acute basophilic leukemia 0 0.0 − − − − − − −
Acute panmyelosis with myelofibrosis 8 2.5 73 75 0.09 0.07 0.06 0.06 1.00
Myeloid sarcoma 2 0.6 78 37 0.02 0.02 0.02 0.02 1.00
AML NOS and AL of ambiguous lineage 58 18.2 74 80 0.66 0.60 0.30 0.45 1.52
Myelodysplastic syndromes 458 100 77 77 5.18 4.06 2.80 3.30 1.16
Refractory anemia 76 16.6 76 74 0.86 0.58 0.56 0.56 0.96
Refractory anemia with ringed sideroblasts 80 17.5 75 76 0.90 0.79 0.40 0.57 1.41
Refractory anemia with excess of blasts 98 21.4 76 76 1.11 0.78 0.68 0.72 0.92
Refractory cytopenia with multilineage 71 15.5 76 78 0.80 0.63 0.46 0.54 1.09
dysplasia
MDS associated with isolated del(5q) 6 1.3 − 68 0.07 − 0.12 0.06 -
MDS unclassifiable 127 27.7 80 81 1.44 1.25 0.60 0.85 1.50**
Myeloproliferative neoplasms 489 100 67 67 5.53 4.93 4.00 4.43 1.10***
Chronic myelogenous leukemia 102 20.9 64 60 1.15 1.13 0.82 0.96 1.32
Polycythemia vera 118 24.1 65 72 1.33 1.46 0.71 1.08 1.62**
Primary myelofibrosis 35 7.2 68 65 0.40 0.36 0.31 0.32 1.19
Essential thrombocythemia 176 36.0 69 65 1.99 1.46 1.77 1.59 0.80
Others 9 1.8 65 55 0.10 0.12 0.06 0.09 2.00
Myeloproliferative neoplasm  unclassifiable 42 8.6 74 80 0.48 0.32 0.29 0.30 0.76
Mast cell diseases 7 1.4 56 62 0.08 0.09 0.06 0.08 1.29
Myelodysplastic/myeloproliferative neoplasms 65 100 79 78 0.74 0.59 0.35 0.44 1.33
Chronic myelomonocytic leukemia 61 93.9 79 79 0.69 0.56 0.32 0.41 1.34
Juvenile chronic myelomonocytic leukemia 0 0.0 − − − − − − −
Atypical chronic myeloid leukemia 4 6.2 79 67 0.05 0.03 0.04 0.03 1.00
Myeloid malignancies 1,331 72 73 15.04 13.06 9.56 11.08 1.17***
N. of cases (number of cases); % (percentage of cases); CR (crude rate per 100,000 inhabitants/year); ASRE (European population standardized incidence rate per 100,000
inhabitants/year); AML (acute myeloid leukemia);  AL (acute leukemia); NOC (not otherwise categorized ); NOS (not otherwise specified); MDS (myelodysplastic syn-
dromes): * (0.05> P <0.03), ** (0.03> P < 0.01), *** (P < 0.01).
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cythemia vera (PV) and essential thrombocythemia (ET) as
malignant diseases. Results of crude rate (CR) and
European standardized incidence rate (ASRE) were
expressed per 100,000 inhabitants/year.
A total of 1,331 cases of MMs were diagnosed in the
province of Girona from 1994 to 2008: 718 men (53.9%)
and 613 women (46.1%). Acute myeloid leukemia (AML)
accounted for 24.0% (319 of 1,331), MDS 34.4% (458 of
1,331), MPN 36.7% (489 of 1,331) including chronic
myeloid leukemia (CML), and myelodysplastic/myelopro-
liferative neoplasms (MDS/MPN) for 4.9% (65 of 1,331). 
The MMs CR was 15.04 and ASRE was 11.08 (13.06 in
men and 9.56 in women), with a statistically significant
male predominance (sex ratio 1.17). Median age was 72
years in men and 73 years in women (Table 1).
Although the highest incidence among MMs groups in
the province of Girona was MPN (ASRE = 4.43), diagnosis
was often made in outpatient settings and this means
these cancers are more likely to be underreported to cancer
registries than other cancers. However, our results were
similar to those reported in south-east England, although
we included mast cell diseases as recommended by the
WHO 2008.5,6 The median age of patients at diagnosis was
67 years and a significant male predominance was found
both overall and also in the PV entity (Table 1).   
Since ICD-O-3 (International Classification of Diseases
for Oncology) was introduced, MDS can now be reported
in cancer registries. Due to changes in MMs classification,
and the advanced age of patients at diagnosis, these dis-
eases have not been as well documented as other patholo-
gies. The most frequent type within this group was MDS
unclassifiable, and the least was 5q- syndrome (Table 1).
The incidence of MDS (ASRE = 3.30) was close to that
reported in south-east England and Germany.6,7 The higher
incidence of MDS in the province of Girona than in the
French study could be due to the fact that the Côte d’Or
Department is a hematologic monographic registry. They
used positive criteria such as karyotype abnormalities or
evolution to a more aggressive type to register cases of
refractory anemia in order to avoid the inclusion of false
cases.8 The lower incidence of MDS in the US may be due
to the underreporting of cases.9,10
The overall ASRE for AML was 2.91, with a statistically
male predominance (sex ratio 1.28). The median age of
AML patients was 68 years, being lower in AML with
recurrent cytogenetic abnormalities and therapy-related
AML. Approximately 54% (171 of 319) of cases were AML
not otherwise categorized, and within this group, the
majority of cases were acute myelomonocytic leukemia
and AML without maturation. The AML and MDS thera-
py-related group was the less frequent within the four
main AML groups (Table 1). The incidence rate of AML in
the province of Girona was similar to that reported in
France, south-east England and Sardinia.6,8,11 Nevertheless,
the proportion of AML with cytogenetic abnormalities in
our cohort was lower than in France and the UK.8,12 This is
probably because karyotype tests were made outside the
province of Girona and information was not always avail-
able for older cases. The most frequent cytogenetic abnor-
mality was the t(15;17), as in France and the UK.8,12
Finally, the myeloid group with the lowest incidence
was MDS/MPN, with an ASRE of 0.44 (Table 1). The
median age at diagnosis was 78 years. Chronic
myelomonocytic leukemia (CMML) was the most fre-
quent entity, comprising more than 90% of all MDS/MPN
cases. Our results were comparable to others reported in
south-east England or Germany.6,7 Differences were found
between our incidence rates and those reported in France,
probably because in the province of Girona some cases of
CMML were recoded as MDS.8 The lower incidence in the
US could be a consequence of underreported cases.9,10 
Significant increases in incidence trends were found in
the MDS, MPN and MDS/MPN groups (Figure 1),
although these could be considered unreliable. The pres-
ence of some gene mutations and the improvements in
diagnostic techniques could be the reasons for these
changes in incidence trends. The discovery of the JAK2
V617F mutation in 2005 could have resulted in an increase
in some MPN, such PV, ET, and primary myelofibrosis,
which have been identified objectively as pathological
since the introduction of molecular biology.13,14No increase
in incidence of AML was found between 1994-2008, sim-
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Figure 1. Trends in standard-
ized incidence rate of myeloid
malignancy WHO categories in
Girona province (1994-2008).
This figure shows the modeled
standardized incidence rate.
Values under the figure repre-
sented the real standardized
incidence rate by year and
myeloid groups.
AML: acute myeloid leukemia; MPN : myeloproliferative neoplasms; MDS/MPN: myelodysplastic/myelo-
proliferative neoplasms; MDS: myelodysplastic syndromes; EAPC: estimated annual percentage change. 
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ilar to results reported from France, the UK and the US.8,12,15
According to our predictions, 7,551 new cases of MMs
will be diagnosed in Spain for the year 2013, of which
1,772 cases will be AML, 2,647 MDS, 2,744 MPN and 388
MDS/MPN. These results are of interest for clinicians and
those involved in public health in order to evaluate the
cost of new treatments for these pathologies. Some limita-
tions of this study must be considered. Classification of
MMs has changed in recent decades and there could be an
underreporting of cases. Also, an increased outpatient
diagnosis over time makes it difficult to ensure complete
coverage of MMs in cancer registries, especially MDS and
MPN. 
This study describes in detail the incidence of MMs in a
large population-based cohort. MPN were the group with
the highest incidence of MMs in the province of Girona
and incidence trends increased significantly in MDS, MPN
and MDS/MPN. Our results show that recent advances in
diagnosis of MMs and an increase in outpatient diagnosis
have resulted in changes in incidence rate trends. 
Gemma Osca-Gelis,1,2,3 Montserrat Puig-Vives,1,2,3 Marc
Saez,2,3 David Gallardo,4 Natalia Lloveras,4
and Rafael Marcos-Gragera1,2,3
1Epidemiology Unit and Girona Cancer Registry, Oncology
Coordination Plan, Department of Health, Autonomous Government
of Catalonia, Catalan Institute of Oncology, Girona Biomedical
Research Institute (IdiBGi), Girona; 2Research Group on Statistics,
Econometrics and Health (GRECS), Universitat de Girona, Girona;
3CIBER in Epidemiology and Public Health (CIBERESP);
4Hematological Service, Catalan Institute of Oncology, Hospital
Universitari Dr. Josep Trueta, Girona, Spain
Funding: This study was supported with the pre-doctoral grant
“Formació Personal Investigador” (FI) from the Autonomous
Government of Catalonia. 
Correspondence: gemma.osca.gelis@gmail.com
doi:10.3324/haematol.2013.084061
Key words: WHO classification, myeloid malignancies,
HAEMACARE project.
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
References
1. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hemato-
logical malignancies. Ann Oncol. 2007;18 Suppl 1:i3-i8.
2. Sant M, Allemani C, Tereanu C, de Angelis R., Capocaccia R, Visser
O, et al. Incidence of hematologic malignancies in Europe by mor-
phologic subtype: results of the HAEMACARE project. Blood.
2010;116(19):3724-34.
3. Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, de
Angelis R, et al. Incidence, survival and prevalence of myeloid malig-
nancies in Europe. Eur J Cancer. 2012;48(17):3257-66.
4. Vardiman JW, Harris NL, Brunning RD. The World Health
Organization (WHO) classification of the myeloid neoplasms.
Blood. 2002;100(7):2292-302.
5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ,
Porwit A, et al. The 2008 revision of the World Health Organization
(WHO) classification of myeloid neoplasms and acute leukemia:
rationale and important changes. Blood. 2009;114(5):937-51.
6. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and
outcome of myeloid malignancies in 2,112 adult patients in south-
east England. Haematologica. 2006;91(10):1400-4.
7. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas
R, et al. Incidence and prevalence of myelodysplastic syndromes:
data from the Dusseldorf MDS-registry. Leuk Res.
2011;35(12):1591-6.
8. Maynadie M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret
F, Bailly F, et al. Twenty-five years of epidemiological recording on
myeloid malignancies: data from the specialized registry of hemato-
logic malignancies of Cote d'Or (Burgundy, France). Haematologica.
2011;96(1):55-61.
9. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes:
incidence and survival in the United States. Cancer.
2007;109(8):1536-42.
10. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries
LA, et al. Epidemiology of myelodysplastic syndromes and chronic
myeloproliferative disorders in the United States, 2001-2004, using
data from the NAACCR and SEER programs. Blood. 2008;112(1):45-
52.
11. Broccia G, Deplano W, Dessalvi P, Giannico B, Luxi G, Chessa E, et
al. Hematological malignancies in the island of Sardinia, 1974-1993:
age and sex distributions and temporal changes in incidence.
Hematol Oncol. 2004;22(3):91-109.
12. Sanderson RN, Johnson PR, Moorman AV, Roman E, Willett E,
Taylor PR, et al. Population-based demographic study of karyotypes
in 1709 patients with adult acute myeloid leukemia. Leukemia.
2006;20(3):444-50.
13. Girodon F, Bonicelli G, Schaeffer C, Mounier M, Carillo S, Lafon I,
et al. Significant increase in the apparent incidence of essential
thrombocythemia related to new WHO diagnostic criteria: a popu-
lation-based study. Haematologica. 2009;94(6):865-9.
14. Schafer AI. Molecular basis of the diagnosis and treatment of poly-
cythemia vera and essential thrombocythemia. Blood. 2006;
107(11):4214-22.
15. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia
incidence and survival in the United States (1973-1998). Cancer.
2003;97(9):2229-35.
haematologica 2013; 98:e97
LETTERS TO THE EDITOR
©F
err
at
 S
tor
ti F
ou
nd
ati
on
No
 co
mm
erc
ial
 us
e
